Immune response from STRIDE, a randomized, phase 2, open label study of sipuleucel-T (sip-T) with concurrent vs sequential enzalutamide (enz) administration in metastatic castration-resistant prostate cancer (mCRPC).

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 5040-5040 ◽  
Author(s):  
David I. Quinn ◽  
Charles G. Drake ◽  
Robert Dreicer ◽  
Emmanuel S. Antonarakis ◽  
Neal D. Shore ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Immune Response ◽  
Phase 2 ◽  
Castration Resistant Prostate Cancer ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Castration Resistant ◽  
Randomized Phase 2

A randomized phase II, open-label study of sipuleucel-T with concurrent or sequential enzalutamide in metastatic castration-resistant prostate cancer (mCRPC).

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. e16071-e16071 ◽  
Author(s):  
David I. Quinn ◽  
Daniel Peter Petrylak ◽  
Christopher Michael Pieczonka ◽  
Andrew Sandler ◽  
Todd DeVries ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Phase Ii ◽  
Castration Resistant Prostate Cancer ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Castration Resistant ◽  
Randomized Phase Ii

Re-treatment with radium-223: An international, prospective, open-label study in patients with castration-resistant prostate cancer and bone metastases.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 5074-5074
Author(s):  
A. Oliver Sartor ◽  
Daniel Heinrich ◽  
Neil Mariados ◽  
María José Méndez-Vidal ◽  
Daniel Keizman ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Metastases ◽  
Castration Resistant Prostate Cancer ◽  
Open Label ◽  
Open Label Study ◽  
Label Study ◽  
Castration Resistant ◽  
Radium 223
Sign in / Sign up

Export Citation Format

Share Document